A5043227502- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Histone Deacetylase Inhibitors Research
- Genomic variations and chromosomal abnormalities
- Protein Degradation and Inhibitors
- Platelet Disorders and Treatments
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Hematopoietic Stem Cell Transplantation
- Blood groups and transfusion
- Retinoids in leukemia and cellular processes
- Bone and Joint Diseases
- Sarcoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Blood disorders and treatments
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
Marien Hospital Düsseldorf
2015-2024
St.-Johannes-Hospital Dortmund
2008-2023
St. Marien Hospital
2023
Helios Kliniken
2019-2020
University of Duisburg-Essen
2018
Essen University Hospital
2018
Klinikum Bremen-Mitte
2018
Heinrich Heine University Düsseldorf
1997-2016
BG Klinikum Duisburg
2010-2016
John Wiley & Sons (United States)
2016
Severe, often refractory anemia is characteristic of the myelodysplastic syndrome associated with chromosome 5q31 deletion. We investigated whether lenalidomide (CC5013) could reduce transfusion requirement and suppress abnormal 5q31- clone in patients this disorder.One hundred forty-eight received 10 mg for 21 days every 4 weeks or daily. Hematologic, bone marrow, cytogenetic changes were assessed after 24 treatment by an intention-to-treat analysis.Among 148 patients, 112 had a reduced...
Purpose The aims of this study were to identify the most significant prognostic factors in myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and changes time develop a dynamic model for predicting survival leukemic evolution that can be applied any during course disease. Patients Methods We studied learning cohort 426 MDS patients diagnosed Department Hematology, San Matteo Hospital, Pavia, Italy, between 1992 2004, validation 739...
Purpose The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of International Prognostic Scoring System (IPSS) 1997, knowledge concerning impact abnormalities has increased substantially. present study proposes new and comprehensive cytogenetic scoring system based on an international data collection 2,902 patients. Patients Methods were included from German-Austrian MDS Study Group (n = 1,193), Risk Analysis Workshop 816),...
To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy.Two-hundred thirty-three (median age, 70 years; range, 90 years) were enrolled; 53% had poor-risk cytogenetics, the median MDS duration at random assignment was 3 months. Primary end point overall survival (OS). Decitabine (15 mg/m(2)) given intravenously over 4 hours three times a day days 6-week cycles.OS...
The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even intensive chemotherapy. In this trial, we compared the antileukemic activity standard induction and consolidation therapy or without addition kinase inhibitor sorafenib in AML.All received cytarabine daunorubicin (7+3 regimen) up to two cycles intermediate-dose consolidation. Two hundred one were equally randomly assigned receive either placebo between chemotherapy subsequently for 1 year after beginning...
Abstract Cancer is a genetic disease, but two patients rarely have identical genotypes. Similarly, differ in their clinicopathological parameters, how genotypic and phenotypic heterogeneity are interconnected not well understood. Here we build statistical models to disentangle the effect of 12 recurrently mutated genes 4 cytogenetic alterations on gene expression, diagnostic clinical variables outcome 124 with myelodysplastic syndromes. Overall, one or more lesions correlate expression...
Purpose Interim positron emission tomography (PET) using the tracer, [18F]fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin lymphomas. We assessed whether PET can guide therapy who are treated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Patients Methods Newly diagnosed received two cycles of CHOP-plus rituximab (R-CHOP) CD20-positive lymphomas-followed by a scan that was evaluated ΔSUVmax method. PET-positive were randomly assigned to...
This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents.In total, 239 were randomly assigned (2:1) treatment (n = 160) placebo 79) once per day (on 28-day cycles). The primary end point was rate transfusion independence (TI)...
// Peter Valent 1,2 , Attilio Orazi 3 David P. Steensma 4 Benjamin L. Ebert 5 Detlef Haase 6 Luca Malcovati 7 Arjan A. van de Loosdrecht 8 Torsten Haferlach 9 Theresia M. Westers Denise Wells 10 Aristoteles Giagounidis 11 Michael Loken Alberto Orfao 12 Lübbert 13 Arnold Ganser 14 Wolf-Karsten Hofmann 15 Kiyoyuki Ogata 16 Julie Schanz Marie C. Béné 17 Gregor Hoermann 18 Wolfgang R. Sperr Karl Sotlar 19 Bettelheim 20 Reinhard Stauder 21 Pfeilstöcker 22 Hans-Peter Horny...
Abstract BACKGROUND Elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) have a poor prognosis, low complete remission (CR) rate, high induction mortality, and short duration. Imatinib (IM) has favorable toxicity profile but limited antileukemic activity in advanced Ph+ALL. combination intensive chemotherapy yielded promising results as front‐line therapy, its value monotherapy newly diagnosed Ph+ALL is not known. METHODS Patients de novo were randomly...
Myelodysplastic syndromes and acute myeloid leukemia exemplify the complexity of treatment allocation in older patients as options range from best supportive care, non-intensive (e.g. hypomethylating agents) to intensive chemotherapy/hematopoietic cell transplantation. Novel metrics for non-disease variables are urgently needed help define each patient. We investigated feasibility prognostic value geriatric/quality life assessments aside established disease-specific 195 aged 60 years or over...